SC
Suvretta Capital
Suvretta Capital is a Series B to Series D stage investment firm. It has made 5 investments. 40% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-d (40% of deals). Average disclosed round size is $168.8M (across 5 rounds with reported amounts).
Portfolio
5
Fund Size
—
Top Stage
Series D
Last 12 Mo
0
Team
AB
Amanda Birdsey-Benson
Managing Director
DF
David Friedman
Managing Director
TW
Thomas Wilkes
Managing Director / Consumer Sector Head
XL
Xavier Le Sieur
Managing Director
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Avalyn Pharma, Inc. | Series D | $100M | Jul 2025 |
| AAvalyn | Series C | $100M | Sep 2023 |
| AAmbrx Inc | Unknown | $45M | Nov 2020 |
 VeraDermics | Series B | $75M | — |
| TTurntide Technologies | Series D | $524M | — |
Top Co-Investors
Catalio Capital Management2 shared
Wellington Management2 shared
F-Prime Capital2 shared
RiverVest Venture Partners2 shared
Eventide Asset Management2 shared
T. Rowe Price2 shared
SR One2 shared
Pivotal bioVenture Partners2 shared
Surveyor Capital2 shared
Novo Holdings A/S2 shared
Rock Springs Capital2 shared
Norwest Venture Partners2 shared
TPG Biotech1 shared
Maverick Ventures1 shared
Adage Capital Management1 shared
Apricot Capital1 shared
Pivotal Life Sciences1 shared
Hopu Investments1 shared
Last updated: 19 September 2026